Cellectar Biosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

FAIR VALUE (Table)

FAIR VALUE (Table)

9 Months Ended

Sep. 30, 2012

Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]

Assets and liabilities measured at fair value on a recurring basis are summarized below:

	September 30, 2012
	Level 1		Level 2		Level 3		Fair Value

Liabilities:
Warrants	$	-	$	21,628	$	-	$	21,628

	December 31, 2011
	Level 1		Level 2		Level 3		Fair Value

Liabilities:
Warrants	$	-	$	23,305	$	-	$	23,305

- Definition

Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.

+ References + Details